CTCBIO Inc Asset Resilience Ratio
CTCBIO Inc asset resilience ratio. CTCBIO Inc (060590) has an Asset Resilience Ratio of 0.00% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of CTCBIO Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CTCBIO Inc (2011–2024)
Asset resilience ratio of CTCBIO Inc from 2011 to 2024. This chart shows how CTCBIO Inc's Asset Resilience Ratio has changed over time. Read 060590 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CTCBIO Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is CTCBIO Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩80.00 | 0.0% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩80.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: CTCBIO Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
CTCBIO Inc Industry Peers by Asset Resilience Ratio
Compare CTCBIO Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
CTCBIO Inc Asset Resilience Ratio by Year (2011–2024)
CTCBIO Inc asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for CTCBIO Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | ₩370.00 ≈ $0.25 |
₩153.69 Billion ≈ $104.15 Million |
-0.03pp |
| 2023-12-31 | 0.03% | ₩50.00 Million ≈ $33.88K |
₩165.86 Billion ≈ $112.40 Million |
-12.93pp |
| 2022-12-31 | 12.96% | ₩24.35 Billion ≈ $16.50 Million |
₩187.90 Billion ≈ $127.34 Million |
+8.41pp |
| 2021-12-31 | 4.55% | ₩7.65 Billion ≈ $5.19 Million |
₩168.23 Billion ≈ $114.00 Million |
-3.71pp |
| 2020-12-31 | 8.26% | ₩14.64 Billion ≈ $9.92 Million |
₩177.17 Billion ≈ $120.07 Million |
-0.65pp |
| 2019-12-31 | 8.91% | ₩16.62 Billion ≈ $11.27 Million |
₩186.50 Billion ≈ $126.39 Million |
+1.60pp |
| 2018-12-31 | 7.31% | ₩14.02 Billion ≈ $9.50 Million |
₩191.69 Billion ≈ $129.90 Million |
+2.72pp |
| 2017-12-31 | 4.60% | ₩8.82 Billion ≈ $5.97 Million |
₩191.80 Billion ≈ $129.98 Million |
+1.05pp |
| 2016-12-31 | 3.55% | ₩6.69 Billion ≈ $4.53 Million |
₩188.68 Billion ≈ $127.86 Million |
+2.44pp |
| 2015-12-31 | 1.11% | ₩2.15 Billion ≈ $1.46 Million |
₩193.61 Billion ≈ $131.21 Million |
-0.77pp |
| 2014-12-31 | 1.88% | ₩3.04 Billion ≈ $2.06 Million |
₩162.12 Billion ≈ $109.87 Million |
-15.22pp |
| 2013-12-31 | 17.10% | ₩25.73 Billion ≈ $17.43 Million |
₩150.48 Billion ≈ $101.98 Million |
+14.55pp |
| 2012-12-31 | 2.54% | ₩3.19 Billion ≈ $2.16 Million |
₩125.36 Billion ≈ $84.96 Million |
+1.69pp |
| 2011-12-31 | 0.86% | ₩801.82 Million ≈ $543.38K |
₩93.33 Billion ≈ $63.25 Million |
-- |
About CTCBIO Inc
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergi… Read more